Prediction of Lymph Node Metastasis in Breast Cancer by Gene Expression and Clinicopathological Models: Development and Validation within a Population-Based Cohort
Open Access
- 1 November 2019
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 25 (21) , 6368-6381
Abstract
Purpose: More than 70% of patients with breast cancer present with node-negative disease, yet all undergo surgical axillary staging. We aimed to define predictors of nodal metastasis using clinicopathological characteristics (CLINICAL), gene expression data (GEX), and mixed features (MIXED) and to identify patients at low risk of metastasis who might be spared sentinel lymph node biopsy (SLNB). Experimental Design: Breast tumors (n = 3,023) from the population-based Sweden Cancerome Analysis Network–Breast initiative were profiled by RNA sequencing and linked to clinicopathologic characteristics. Seven machine-learning models present the discriminative ability of N0/N+ in development (n = 2,278) and independent validation cohorts (n = 745) stratified as ER+HER2−, HER2+, and TNBC. Possible SLNB reduction rates are proposed by applying CLINICAL and MIXED predictors. Results: In the validation cohort, the MIXED predictor showed the highest area under ROC curves to assess nodal metastasis; AUC = 0.72. For the subgroups, the AUCs for MIXED, CLINICAL, and GEX predictors ranged from 0.66 to 0.72, 0.65 to 0.73, and 0.58 to 0.67, respectively. Enriched proliferation metagene and luminal B features were noticed in node-positive ER+HER2− and HER2+ tumors, while upregulated basal-like features were observed in node-negative TNBC tumors. The SLNB reduction rates in patients with ER+HER2− tumors were 6% to 7% higher for the MIXED predictor compared with the CLINICAL predictor accepting false negative rates of 5% to 10%. Conclusions: Although CLINICAL and MIXED predictors of nodal metastasis had comparable accuracy, the MIXED predictor identified more node-negative patients. This translational approach holds promise for development of classifiers to reduce the rates of SLNB for patients at low risk of nodal involvement.Keywords
All Related Versions
Funding Information
- Swedish Cancer Society (CAN 2016/659, CAN 2018/685)
- Skåne County Council's Research and Development Foundation (2016/623611)
- ALF (2014/434901, 2018/40612, 2019/40304)
- The Swedish Breast Cancer Association (2017/1213)
- Mrs. Berta Kamprad Foundation (FBKS 2018-3-166)
- Crafoord Foundation (20180543)
- Erling-Persson Family Foundation (2018/1008)
This publication has 51 references indexed in Scilit:
- Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: entinel node vs bservation after axillary ltraSou )The Breast, 2012
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transitionBreast Cancer Research, 2012
- Nodal Status and Clinical Outcomes in a Large Cohort of Patients With Triple-Negative Breast CancerJournal of Clinical Oncology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node MetastasisJAMA, 2011
- Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer StudyClinical Cancer Research, 2010
- Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signaturesBreast Cancer Research, 2008
- The Prognostic Significance of Micrometastases in Breast Cancer: A SEER Population-Based AnalysisAnnals of Surgical Oncology, 2007
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001